尼莫地平联合氟桂利嗪治疗偏头痛临床评价  

Clinical Evaluation of Nimodipine Combined with Flunarizine in Treating Migraine

作　　者：赵英兵 聂元文[1] 徐甜颖 

机构地区：[1]牡丹江医学院第二附属医院,黑龙江牡丹江157000

出　　处：《中国药业》2017年第9期53-55,共3页China Pharmaceuticals

摘　　要：目的探讨尼莫地平联合氟桂利嗪治疗偏头痛的临床疗效。方法将医院2015年4月至2016年10月收治的48例偏头痛疾病患者随机分为两组,各24例。单一用药组采用单纯尼莫地平治疗,联合用药组在此基础上加用氟桂利嗪治疗。比较两组患者的临床疗效,疾病发作情况、疼痛程度,患者血液流变学相关指标差异,药品不良反应发生情况。结果联合用药组患者偏头痛治疗总有效率为95.83%,明显高于单一用药组的75.00%(P<0.05);治疗前,两组疾病发作情况、疼痛程度无显著差异(P>0.05),治疗后,联合用药组疾病发作情况、疼痛程度改善幅度较单一用药组更大(P<0.05);治疗前两组患者血液流变学相关指标无显著差异(P>0.05),治疗后,联合用药组血液流变学相关指标改善幅度较单一用药组更大(P<0.05);两组均无严重不良反应发生。结论尼莫地平联合氟桂利嗪治疗偏头痛疗效确切,可有效改善血液流变学指标,控制病情发作,减轻患者痛苦,且无明显不良反应,安全性高,值得临床推广。Objective To investigate the clinical efficacy of Nimodipine combined with Flunarizine in treating migraine. Methods Totally 48 patients with migraine admitted to our hospital from April 2015 to October 2016 were randomly divided into two groups, 24 cases in each group. The single prodrug group was treated with Nimodipine, on this basis, the combined drug group was added Flunarizine. The clinical efficacy, the onset of disease, the degree of pain, the difference in the index of blood rheology and the adverse drug reactions of the two groups were compared. Results The total efficiency rate of the combined drug group was 95.83%, which was significantly higher than 75.00% of the single prodrug group（P 〈 0.05）. Before treatment, the onset of disease, degree of pain in the two groups showed no significant difference（P 〉 0. 05）, but those improved more significantly in the combined drug group after treatment（P 〈 0.05）. Before treatment, the index of blood rheology in the two groups showed no significant difference（P 〉 0.05）, but that improved more significantly in the combined drug group after treatment（ P 〈 0. 05）. There was no serious adverse drug reaction occurred in the two groups. Conclusion Nimodipine combined with Flunarizine in treating migraine disease has good clinical curative effect, can effectively improve the index of blood rheology, control seizures, and relieve the pain of patients without obvious adverse drug reaction, it is safety and worthy of clinical promotion.

关 键 词：尼莫地平 氟桂利嗪 偏头痛 临床疗效 

分 类 号：R969.4[医药卫生—药理学] R971.1[医药卫生—药学]